{"data":[{"accessionNo":"0000902219-26-000277","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Wellington Group Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":7131084,"percentOfClass":6.8,"filedAt":"2026-08-13"},{"accessionNo":"0000902219-26-000277","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Wellington Investment Advisors Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":7131084,"percentOfClass":6.8,"filedAt":"2026-08-13"},{"accessionNo":"0000902219-26-000277","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Wellington Management Group LLP","reportingCik":null,"personType":"HC","sharesOwned":7131084,"percentOfClass":6.8,"filedAt":"2026-08-13"},{"accessionNo":"0000902219-26-000277","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Wellington Management Company LLP","reportingCik":null,"personType":"IA","sharesOwned":7131084,"percentOfClass":6.4,"filedAt":"2026-08-13"},{"accessionNo":"0000315066-26-002233","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001658247","issuerName":"CRINETICS PHARMACEUTICALS INC","ticker":"CRNX","cusip":"22663K107","securityClass":"COMMON STOCK","eventDate":"2026-07-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":1439890.88,"percentOfClass":1.4,"filedAt":"2026-08-07"},{"accessionNo":"0000315066-26-002233","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001658247","issuerName":"CRINETICS PHARMACEUTICALS INC","ticker":"CRNX","cusip":"22663K107","securityClass":"COMMON STOCK","eventDate":"2026-07-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":1439890.88,"percentOfClass":1.4,"filedAt":"2026-08-07"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Wehrly, Mark C.","reportingCik":null,"personType":"HC,IN","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Management, L.L.C.","reportingCik":null,"personType":"IA,OO","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Dapice Joshua J.","reportingCik":null,"personType":"HC,IN","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Dreyfuss, Philip D.","reportingCik":null,"personType":"HC,IN","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Dunn Hannah E.","reportingCik":null,"personType":"HC,IN","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Gehani, Varun N.","reportingCik":null,"personType":"HC,IN","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Giauque, Nicolas","reportingCik":null,"personType":"HC,IN","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Husen, Avner A.","reportingCik":null,"personType":"HC,IN","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Kim, David T.","reportingCik":null,"personType":"HC,IN","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Luo Patrick (Cheng)","reportingCik":null,"personType":"HC,IN","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Linn, Michael G.","reportingCik":null,"personType":"HC,IN","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Roberts, Jr., Thomas G.","reportingCik":null,"personType":"HC,IN","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Saito Edric C.","reportingCik":null,"personType":"HC,IN","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Short Daniel S.","reportingCik":null,"personType":"HC,IN","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Spokes, Andrew J. M.","reportingCik":null,"personType":"HC,IN","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Warren, John R.","reportingCik":null,"personType":"HC,IN","sharesOwned":8989098,"percentOfClass":8.5,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Partners, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Institutional Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Institutional Partners II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Institutional Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Four Crossings Institutional Partners V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Offshore Investors II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital (AM) Investors, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital F5 Master I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Healthcare Partners Master, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Institutional (GP) V, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon F5 (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03"},{"accessionNo":"0000908834-26-000365","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Healthcare Partners (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03"},{"accessionNo":"0000902219-26-000169","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Wellington Management Group LLP","reportingCik":null,"personType":"HC","sharesOwned":8157204,"percentOfClass":7.8,"filedAt":"2026-05-15"},{"accessionNo":"0000902219-26-000169","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Wellington Investment Advisors Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":8157204,"percentOfClass":7.8,"filedAt":"2026-05-15"},{"accessionNo":"0000902219-26-000169","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Wellington Group Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":8157204,"percentOfClass":7.8,"filedAt":"2026-05-15"},{"accessionNo":"0000902219-26-000169","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Wellington Management Company LLP","reportingCik":null,"personType":"IA","sharesOwned":8157204,"percentOfClass":7.4,"filedAt":"2026-05-15"},{"accessionNo":"0000938206-26-000029","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"DRIEHAUS CAPITAL MANAGEMENT LLC","reportingCik":null,"personType":"IA","sharesOwned":6395922,"percentOfClass":6.11,"filedAt":"2026-05-15"},{"accessionNo":"0000080255-26-000423","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"CRINETICS PHARMACEUTICALS IN","ticker":"CRNX","cusip":"22663K107","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"T. Rowe Price Associates, Inc.","reportingCik":null,"personType":"IA","sharesOwned":5355011,"percentOfClass":5.1,"filedAt":"2026-05-15"},{"accessionNo":"0002100119-26-000284","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals Inc","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Vanguard Capital Management","reportingCik":null,"personType":"IA","sharesOwned":5440646,"percentOfClass":5.19,"filedAt":"2026-04-29"},{"accessionNo":"0000102909-26-001041","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals Inc","ticker":"CRNX","cusip":"22663K107","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-26"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Warren, John R.","reportingCik":null,"personType":"IN","sharesOwned":8024098,"percentOfClass":8.5,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Dapice Joshua J.","reportingCik":null,"personType":"IN","sharesOwned":8024098,"percentOfClass":8.5,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Dreyfuss, Philip D.","reportingCik":null,"personType":"IN","sharesOwned":8024098,"percentOfClass":8.5,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Dunn Hannah E.","reportingCik":null,"personType":"IN","sharesOwned":8024098,"percentOfClass":8.5,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Gehani, Varun N.","reportingCik":null,"personType":"IN","sharesOwned":8024098,"percentOfClass":8.5,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Giauque, Nicolas","reportingCik":null,"personType":"IN","sharesOwned":8024098,"percentOfClass":8.5,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Husen, Avner A.","reportingCik":null,"personType":"IN","sharesOwned":8024098,"percentOfClass":8.5,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Kim, David T.","reportingCik":null,"personType":"IN","sharesOwned":8024098,"percentOfClass":8.5,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Linn, Michael G.","reportingCik":null,"personType":"IN","sharesOwned":8024098,"percentOfClass":8.5,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Luo Patrick (Cheng)","reportingCik":null,"personType":"IN","sharesOwned":8024098,"percentOfClass":8.5,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Roberts, Jr., Thomas G.","reportingCik":null,"personType":"IN","sharesOwned":8024098,"percentOfClass":8.5,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Saito Edric C.","reportingCik":null,"personType":"IN","sharesOwned":8024098,"percentOfClass":8.5,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Short Daniel S.","reportingCik":null,"personType":"IN","sharesOwned":8024098,"percentOfClass":8.5,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Spokes, Andrew J. M.","reportingCik":null,"personType":"IN","sharesOwned":8024098,"percentOfClass":8.5,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Wehrly, Mark C.","reportingCik":null,"personType":"IN","sharesOwned":8024098,"percentOfClass":8.5,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Partners, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":7826338,"percentOfClass":8.2,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Healthcare Partners Master, L.P.","reportingCik":null,"personType":"PN","sharesOwned":4682318,"percentOfClass":4.9,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Healthcare Partners (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":4682318,"percentOfClass":4.9,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital Offshore Investors II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1369733,"percentOfClass":1.4,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital Institutional Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":709270,"percentOfClass":0.7,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":584527,"percentOfClass":0.6,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon F5 (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":197760,"percentOfClass":0.2,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital F5 Master I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":197760,"percentOfClass":0.2,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital Institutional Partners II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":168850,"percentOfClass":0.2,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Four Crossings Institutional Partners V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":135338,"percentOfClass":0.1,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital Institutional Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":103335,"percentOfClass":0.1,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital (AM) Investors, L.P.","reportingCik":null,"personType":"PN","sharesOwned":72967,"percentOfClass":0.1,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Institutional (GP) V, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":135338,"percentOfClass":0.1,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Patel, Rajiv A.","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Fried, Richard B","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-05"},{"accessionNo":"0000908834-26-000040","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Seybold, William","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-05"},{"accessionNo":"0000902219-25-000398","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Wellington Investment Advisors Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":8381991,"percentOfClass":8.9,"filedAt":"2025-11-12"},{"accessionNo":"0000902219-25-000398","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Wellington Management Group LLP","reportingCik":null,"personType":"HC","sharesOwned":8381991,"percentOfClass":8.9,"filedAt":"2025-11-12"},{"accessionNo":"0000902219-25-000398","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Wellington Group Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":8381991,"percentOfClass":8.9,"filedAt":"2025-11-12"},{"accessionNo":"0000902219-25-000398","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001658247","issuerName":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Wellington Management Company LLP","reportingCik":null,"personType":"IA","sharesOwned":8381991,"percentOfClass":8.4,"filedAt":"2025-11-12"}],"updatedAt":"2026-10-14T05:15:57.387Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}